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Rethinking the composition of a rational
antibiotic arsenal for the 21st century
The importance of the human microbiome in health may be the single most valuable development in our conception
of the microbial world since Pasteur’s germ theory of the 1860s. Its implications for our understanding of health
and pathogenesis are profound. Coupled with the revolution in diagnostics that we are now witnessing – a revolution
that changes medicine from a science of symptoms to a science of causes – we cannot continue to develop antibiotics
as we have for the past 80 years. Instead, we need to usher in a new conception of the role of antibiotics in treatment:
away from single molecules that target broad phylogenetic spectra and towards targeted molecules that cripple
the pathogen while leaving the rest of the microbiome largely intact.
Beginning with the use of penicillin in World
War II, we have witnessed a recurrent cycle:
novel antibiotics are discovered, put into widespread use and soon rendered clinically ineffective by the inevitable rise of resistant pathogenic
strains. For the first half-century of the age of
antibiotics this pattern was viewed as an inconvenience, but not as a real threat. The microbial
world appeared to offer up a virtually endless
source of potential lead compounds. Coupled
with progress in organic synthesis, which
made the rapid modification of existing smallmolecule scaffolds possible, new antibiotic leads
seemed in vast supply and resistance was simply the inevitable price of doing business with
rapidly evolving pathogens.
Skip ahead 50 years and the price we pay for
resistance has become untenable. Pathogenic
microbes, once easily controlled by antimicrobial drugs, now frequently fail to respond to
many antibiotics [1,2]. Multiply resistant pathogenic strains have emerged in a broad range of
species, including, among others, Staphylococcus
aureus, Mycobacterium tuberculosis, Pseudomonas
aeruginosa, Salmonella enterica and Enterococcus
faecium [3–7]. This new situation is not merely
an inconvenience – it has devastating societal,
economic and human health impacts. Indeed,
the entire treatment landscape for bacterial infections has been changed. Resistance significantly
increases the length of hospitalization, complicates the treatment of other conditions, and may
require the use of more toxic alternative treatments. More ominous still is the marked increase
in mortality from both Gram-negative and
-positive infections associated with ‘inappropriate
antibiotic treatments’ where resistant pathogens

fail to respond to the course of treatment [8]. The
cost of treating infectious disease has increased
drastically. In the USA alone, antibiotic-resistant
infections are estimated to result in US$20 billion
dollars in excess healthcare costs and $35 billion
in societal costs [9,10].
The increased prevalence of antibiotic resistance is an expected outcome of evolution. Any
population of organisms will exhibit heritable
variability. In the case of bacterial populations,
some proportion (often in the range of 1 in
1,000,000 cells) exhibits the ability to survive
antibiotic exposure. When a person takes an
antibiotic, the drug kills the defenseless bacteria, while simultaneously selecting those variants
able to resist it. These renegade bacteria then
multiply and rapidly increase in frequency. The
antibiotic does not cause the resistance, but promotes its spread by creating a situation where an
already existing resistant variant can flourish.
In addition to this selection for resistant strains,
we have now become aware of a second, equally
deleterious consequence of antibiotic exposure:
the disruption of the commensal human microbiome. The human body is a complex mosaic
composed of nine parts microbial cells to one
part human cells. The overwhelming majority of these commensal microbial partners,
key players in maintaining human health, now
become the collateral targets of any topical or
ingested antibiotic. Under pressure from the
antibiotic, many of these commensals evolve or
acquire resistance – mechanisms that become
part of the interspecific global trade in resistance
determinants constantly underway in the bacterial world. Given our coarse approach to treating bacterial infections, the rise and spread of
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resistance should come as no surprise. What is,
instead, surprising is that resistance is not more
widespread.
Current approaches
Public and private approaches to deal with the
now predictable evolution of bacterial resistance
fall into two distinct categories [2,11], restricting
the use of antibiotics and developing new ones.
The first of these has resulted in an increase in the
monitoring of antibiotic resistance, coupled with
significant efforts to curb the indiscriminate use
of antibiotics in order to extend their useful life
span [2,12]. Efforts in this category include more
stringent criteria prior to antibiotic prescription,
more sensitive diagnostics prior to antibiotic
use, increased emphasis on patient compliance,
including use of full antibiotic courses, reduction
and targeting of antibiotic use in food supplies
(including animal feed and poultry processing)
and an overall curb on the antibiotic load present
in the environment [8,9,13]. The recent release of
US FDA guidance on the judicious use of medically important antimicrobial drugs in foodproducing animals suggests that the regulatory
landscape may be poised to respond to this critical factor in resistance evolution [14]. We should
be well beyond the point of questioning whether
our use of antibiotics has selected for resistance.
Attention can now be turned to those measures
that will extend the usefulness of the relatively few
antibiotics that retain broad efficacy. While efforts
directed at educating physicians, patients and the
general public have increased our awareness of the
problem of antibiotic resistance and have, in some
cases, resulted in a reduction in the inappropriate
use of antibiotics, they do not obviate the need to
develop new ones. We stand at a critical juncture
in this regard. One option is to continue to discover and develop new antibiotics as we have over
the past half-century. That approach has involved
the identification of compounds that exhibit high
activity, broad range and low toxicity, while at the
same time meeting a variety of criteria involving
stability and deliverability. Within that framework, the prospect of antibiotic resistance is clearly
seen as a major potential limitation on the utility
and life span of any novel antibiotic. However, its
emergence is usually treated as an unfortunate,
undesirable, but unavoidable outcome of battling
infectious agents.
A new approach
Today, both our faith in an endless supply of
new clinically useful antimicrobials and our
1232
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perspective on the challenges posed by antibiotic
resistance have undergone radical transformation. The pipeline for new antibiotic leads has
slowed to a trickle [15] and the incidence of
pathogens resistant to virtually all currently
employed antibiotics is on the rise [3,5,7]. For
the first time since the discovery of antibiotics,
we face the prospect of untreatable infections.
This situation, alarming as it is, also presents
an opportunity to radically rethink the composition of a rational antibiotic arsenal for the
21st century clinic. In addition to the established
criteria for activity, efficacy and toxicity, we contend that two additional criteria must be taken
into account in the design of new antimicrobial
compounds:
n Resistibility: the frequency at which resistance
to a novel antibiotic arises and the resulting
fitness cost to the pathogen of that resistance;
Specificity: the extent to which a novel
antibiotic can be directed only against pathogenic strains while leaving the composition and
structure of the commensal human microbiome
undisturbed.
We argue that this second, more radical
approach to antibiotic development is needed.
Under this new paradigm, we acknowledge
the lessons learned in the laboratory and in the
clinic and incorporate the discoveries in genetics,
genomics and microbial ecology into the search
for and design of new antimicrobials. This proposed paradigm shift requires our dedicated
focus on the infectious agent within the context
of its occurrence in the human microbiome. It
is no longer reasonable to spend a billion dollars
developing a drug that will target the majority
of beneficial bacteria, as well as the numerically
insignificant (but clinically relevant) pathogens,
thereby imposing massive and widespread selection for resistance, while concurrently depleting
the diversity of our microbiome. Our micro
biome is an essential factor in maintaining
human health and efforts to treat disease must
take this into account [16,17].
Fortunately, just as fungi and bacteria offered
a diversity of solutions to fighting infectious disease in the early 20th century, in the form of
penicillins, tetracyclines and so forth, they are
similarly poised to provide a solution to our current dilemma. In the billions of years of their
evolution, microbes have evolved an extensive
palette of antimicrobials. This palette should be
the starting point in our search for new, smart
antimicrobials: a plethora of potential drug
n
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candidates with compelling features is there
to be found. The antimicrobials found in the
microbial world exhibit a range of specificities and modes of action, from the exquisitely
highly targeted killing by certain bacteriocins
and bacteriophage, to the broad and indiscriminate action of bacterial lysozymes. Add to this
list the exciting new candidates resulting from
bioengineering efforts, such as RNA-based
therapeutics, immunomodulating agents, phage
lysins and antimicrobial peptides [18,19], and the
number and range of potential drug candidates
is encouraging.
Our drug-discovery task becomes even
less daunting when we realize that until now
we have essentially ignored some of the most
successful solutions to the challenge of eliminating infectious agents. The magic bullets
of the 20th century, that is, broad-spectrum
antibiotics, embody a strategy rarely seen in the
microbial world. Instead, most evolved antimicrobials act specifically against their closest
competitors, those species consuming the same
limited resources or inhabiting the same limited niche [20,21]. Employing a broad-spectrum,
indiscriminate killing approach, as we have done
by using traditional antibiotics, destroys the
very own community of the microbe – and our
essential microbiome. Contrary to the common
perception of microbes growing as single species
on a Petri plate, microbes in nature seldom live
alone. Instead, they live in complex multispecies
communities, with species dependent upon each
other for their very survival. Our use of conventional antibiotics has essentially ignored this
critical feature of microbial ecology, resulting
in devastating collateral damage to the normal
human microflora. We contend that the development of new drugs must take into account
the potential for collateral damage. The good
news is that there already exists an abundance
of promising drug candidates that do just that.
Bacteriocins
The potent arsenal of drugs deployed by microbes
is remarkable in its diversity. Let us turn to one of
the most common superfamily of antimicrobials,
the bacteriocins. Both in terms of abundance
and diversity, bacteriocins contend for the prize
as the primary mechanism of bacterial defense in
nature [20–22]. Bacteriocins are loosely defined as
biologically active peptides with a bacteriocidal
mode of action [23–25], which, although variable
among bacteriocin types, are all distinct from
those of current chemotherapeutic agents [18].
future science group
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The family includes a diversity of proteins in
terms of size, microbial targets, modes of action
and immunity mechanisms. Most, however, are
highly specific in killing or inhibition activity,
often active only against close relatives of the
producing strains [23–26]. These potent toxins
are produced by all major lineages of bacteria,
and within a species tens or even hundreds of
different kinds of bacteriocins can be identified
[22]. Klaenhammer noted over 20 years ago that
99% of all bacteria may make at least one bacteriocin and the only reason more have not been
isolated is that very few researchers have looked
for them [27]. That statement remains fundamentally true today; we have only just begun to tap
the diversity of this superfamily of potent toxins.
Bacteriocins exhibit numerous characteristics
that underscore their viability as alternatives to
conventional antibiotics [20,28]. First, bacteriocins active against all known human and animal pathogens already exist. As noted above,
tens or even hundreds can be isolated from a
single bacterial species. Furthermore, bacteriocins with a spectacular range of specificities also
already exist, ranging from strain-specific moieties to those able to target all Gram-negative
or -positive bacteria. A simple, rapid screen of
a few hundred strains from a target pathogen,
or its close relatives, will almost certainly reveal
numerous compelling compounds [27,29–32].
Furthermore, the long, rich history of research
on bacteriocin structure and function, and the
resulting catalog of structures available in the literature, makes bioengineering-specific activities
a straightforward task. The potency, specificity
and stability of bacteriocins is manipulated by
simply cutting and pasting the desired features
from one bacteriocin onto another [33–35].
Bacteriocins boast a remarkable potency,
many display single-hit kinetics: a single molecule entering the target pathogen will do the
job [25,26]. They also act rapidly, inhibiting or
killing within seconds of encountering a target
cell, in sharp contrast to conventional antibiotics
that often require actively growing cells. In fact,
bacteriocin MIC values rival those of traditional
antibiotics [36,37]. Equally compelling, bacteriocins are stable under a wide range of temperatures (from -20 to +65°C) and other environmental challenges, such as pH [38–40]. Numerous studies attest to the ability of bacteriocins to
retain activity under a wide range of potential
therapeutic conditions, including application on
the skin and in the throat, bladder, bloodstream
and intestines [18,38–47].
www.future-science.com
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Industrial production methods have been
developed for several bacteriocins [42,46]. Nisin,
a bacteriocin produced by Lactococcus lactis,
achieved generally recognized as safe (GRAS)
status from the FDA in 1988 [41]. It has since
been widely used as a food preservative and
in numerous animal production applications,
including prevention of Salmonella spp. colonization of chicken skins and surface-related
infections such as mastitis in cows [18]. The
industrial production methods of nisin and
numerous additional bacteriocins of lactic acid
bacteria are particularly well studied [45,47,48]. In
fact, a global leader in the antimicrobial preservatives industry, Danisco A/S, recently acquired
Aplin and Barrett of the UK and their primary
production facility of nisin. The entry of large
biopreservative manufacturers into the bacteriocin production market signals a key, dramatic
shift in the industrial perception of the hurdles
involved in peptide production.
A further crucial benefit of bacteriocins is
the low or nonexistent toxicity to humans and
other mammals [18,43,49–56]. Studies are mounting that demonstrate that bacteriocins have
minimal impact on host cells, primarily due to
their exquisitely targeted modes of action against
bacteria (for a recent review see [49]). These studies underscore the low toxicity of bacteriocins
and highlight the vast potential of bacteriocins
as therapeutic agents [18,43,49–54]. The lack of
bacteriocin toxicity is perhaps less remarkable
when one considers that many, perhaps even
most, members of our microbiome are producing
them in and on our bodies.
Given the remarkable therapeutic properties
of bacteriocins, it should come as no surprise
that there is growing interest in their commercialization [18,57–59]. Several companies are
already working on bringing bacteriocin-based
approaches to the market. AvidBiotics (CA,
USA) is currently exploring the use of bacteriocins from Pseudomonas spp., known as pyocins,
in food safety, animal health and environmental management. Another company, Bacteriotix
(MA, USA), is investigating the use of bacteriocins against urinary tract (UTIs) and skin infections. Several additional companies, such as Blis
Technologies Ltd (New Zealand), are using these
polypeptides in oral care products. Novacta Biosystems (UK) is also working on a bacteriocin
treatment for the pathogen Clostridium difficile.
These are just a few of the pioneering companies
seeking to develop bacteriocins as a new tool in
our antimicrobial toolbox.
1234
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The use of bacteriocins will ultimately select
for resistant strains, just as is the case with conventional antibiotics. However, because their
therapeutic use would be directed at specific
infections, the intensity of resistance selection
is dramatically decreased. Even more compelling, by combining two or three bacteriocins, a
cocktail can be produced that reduces the resistance frequency by several orders of magnitude,
effectively eliminating resistance as an outcome
(Figure 1). Table 1 represents a second approach
to resistance elimination, the use of a single bacteriocin with targeted substitutions that result
in highly efficacious toxins with slightly altered
specificity. Use of two or more of these variants
results in a significantly reduced frequency of
resistance [32].
Given that bacteriocins are ancient, widespread and in constant use by many bacterial
species to displace competitors and invade novel
environments, how have they remained a viable,
highly effective means of bacterial defense? The
answer is twofold. First, because these toxins target a minute fraction of a microbial community,
the selection for mutations that confer resistance
is not taking place in multiple species simultaneously, as is the case with broad-spectrum
antibiotics. Second, bacteriocins occur in constantly changing and evolving combinations,
thus, allowing the producer strains in nature
to keep pace with emergent resistance in target
strains [60]. It is precisely this strategy – targetspecific, highly active antimicrobials supplied in
changing combinations – that we argue should
be emulated in our future therapeutic approach.
We are convinced that this coupling will result
in combinations that will be effective in vivo
and greatly retard the emergence of resistance
in target pathogens. We contend that the natural
ecology of antibiotics has much to teach us – not
only regarding potential lead compounds, but
also about the rational therapeutic use of anti
biotics. The time is right to assess the therapeutic
potential of this highly diverse and abundant
class of naturally occurring antimicrobials.
Bacteriophages
Bacteriophages represent a second family of compelling targeted drugs. Phage therapy involves
the application of bacteriophages that, when
encountering a specific pathogenic bacteria,
can infect and kill them. However, before killing the cell, the phage directs the bacterial host
to produce phage progeny, which are released
during host lysis. Thus, phages are unique in
future science group
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their ability to increase their numbers when in
the presence of their bacterial targets [61]. Similar
to bacteriocins, many phages are active against a
single or relatively few bacterial strains or species.
In fact, phage therapy is based upon the concept
of cocktails, which can include numerous different phage types. Intestiphage, a product available in Georgia and Russia, contains a cocktail of
phage that targets over 20 different pathogenic
gastrointestinal bacteria [61]. The result of the
narrow killing spectrum for phage and bacteriocins is a lower potential for side effects associated
with dysbiosis, a negative impact on important
normal bacterial flora.
Phages possess several additional features that
make them compelling as therapeutic alternatives. First, is their extraordinary killing efficiency. As opposed to chemical antibiotics, only
a single phage is needed to kill a single bacterium
[62]. Furthermore, a small inoculum of phage,
which then reproduces within the target pathogen, is often sufficient to kill even dense bacterial
infections. This potential for phages to increase
in density in situ could potentially reduce treatment costs and may improve product safety,
since phages only increase in density when the
target bacteria are present [63]. Phages tend to
be bactericidal, in contrast with many conventional antibiotics [64]. Since they consist mostly
of nucleic acids and proteins, phages are inherently nontoxic [63,65,66]. However, phages can
interact with the immune system, at least potentially resulting in harmful immune responses,
though there is little evidence that this actually
is a concern during treatment [62,67–69]. Because
phages infect and kill using mechanisms that
differ from those of antibiotics, specific anti
biotic resistance mechanisms do not translate
into mechanisms of phage resistance. Phages
consequently can be readily employed to treat
antibiotic-resistant infections [62,67,68,70]. Phages
have a demonstrated ability to clear biofilms,
perhaps by lysing one bacterial layer at a time,
or due to the display of biofilm exopolymerdegrading depolymerases [61]. The industrial
costs of phage production are not out of line with
the costs of pharmaceutical production, while
the costs of discovery can be relatively low [63,66].
One area of concern with phage therapy is
the potential host response to phage presence.
However, numerous studies have revealed that
phage therapy rarely, if ever, results in more than
minor side effects [61,71–73]. Indeed, the immuno
logical response of phage presence in animals has
been studied for over a half a century and no
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Colicins and combinations

Figure 1. Colicin combinations reduce resistance frequency by several
orders of magnitude.
Adapted with permission from [32] .

substantial anaphylaxis has been reported [74–77].
Indeed, some studies have indicated a positive
impact of phages on immune system functioning
[68] and have explored potential phage antitumor
properties [74]. A second area of concern relates to
ability of some phages to modify host bacteria in
ways that could make them more pathogenic, or
to release host toxins during cell lysis. However,
cell lysis and toxin release can also be induced by
treatment with traditional antibiotics.
Perhaps the most significant challenge to the
development of phages as alternative therapeutic
agents is simply the lack of familiarity of western medicine with them. This situation may be
poised to change as several phage products have
now been classified by the FDA as GRAS, registered by the Environmental Protection Agency,
or approved for use by the United States Department of Agriculture [63,78]. It is important to note
that therapeutic phages have been used to treat
bacterial infections in eastern Europe for over
80 years [79]. As early as 1921, phage therapy was
used to treat staphylococcal skin infections [62].
During World War II, bacteriophages were used
to treat bacterial infections on the battlefields
Table 1. Targeted substitutions result in efficacious toxins with
slightly altered specificity.
Colicin variant

Altered residues

Relative MIC

Colicin E9.0
Colicin E9.1
Colicin E9.2
Colicin E9.3
Colicin E9.4

None
Leu293Arg
Leu293His
Arg291His
Arg298His

1.0
1.3
0.7
1.6
2.5

www.future-science.com
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by the former Soviet Union [80]. Early on,
American and French pharmaceutical companies demonstrated interest in this approach and
began to manufacture bacteriophage products.
In the 1940s, the Eli Lilly Company (IN, USA)
produced seven phage products for human use.
Bacteriophages were primarily used for treating
bacterial infections caused by Staphylococcus,
Streptococcus, Escherichia coli and Neisseria. A
variety of infections responded to bacteriophage
therapy, including purulent infections of the skin
and mucous membranes, upper respiratory tract
infections, vaginitis and ear mastoid infections
[79]. However, with the advent of antibiotics,
commercial production of therapeutic phages
quickly ceased in the USA.
Phages are currently being used therapeutically in the Republic of Georgia and Poland
to treat bacterial infections that fail to respond
to conventional antibiotics [61]. In the west, no
therapies are currently authorized for use on
humans. However, as mentioned above, the
FDA recently gave its first official approval to
the use of phage in food production with the
approval of ListShield™ (a phage preparation
targeted against Listeria monocytogenes) created
by Intralytix (MD, USA) and the granting of
GRAS status. Agricultural applications include
the use of phages against Campylobacter, Escherichia and Salmonella in farm animals, Lactococcus and Vibrio pathogens in aquaculture,
and Erwinia and Xanthomonas in plants of
agricultural importance. Several companies seek
to bring phage therapy into the western world,
including PhageTech (Canada), Novolytics (UK)
and GangaGen (India, USA and Canada). Phage
therapy has been attempted for the treatment of
numerous infections, including dysentery, gingivitis, UTIs, poly-microbial biofilms on chronic
wounds, ulcers and infected surgical sites [81–83].
In 2007 a Phase I/II clinical trial was completed
at the Royal National Throat, Nose and Ear Hospital (London, UK), employing bacteriophage to
treat P. aeruginosa infections (otitis) [84]. Phase I
clinical trials have now been completed in the
Southwest Regional Wound Care Center (Texas,
USA) for an approved cocktail of phages against
bacteria, including P. aeruginosa, S. aureus and
Escherichia coli [73].
Other targeted approaches
Although bacteriocins and bacteriophages represent the largest families of targeted drugs currently being explored for use in treating infectious
disease, other targeted approaches to dealing with
1236
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infectious disease are rapidly catching on. These
approaches include the use of nanoparticles
designed to interact with specific pathogens
[85,86], RNAi molecules that interact with specific
sequences [87,88] and immunomodulatory interventions tailored against particular agents [89,90].
One of the leading contenders in the hunt for
novel targeted therapeutics is a class of molecules
that specifically block pathogen communication
and, thus, inhibit pathogenicity rather than kill
the cells. Quorum sensing (QS) is a system by
which certain bacteria can monitor their own
population density. They secrete specific autoinducer molecules, which, when concentrations
reach critical threshold values, trigger specific
response systems, causing the induction of sets
of genes that are only expressed at high population density. Some of these genes enable the bacteria to form biofilms, making the cells virtually
untouchable by conventional antibiotics. One
of the first companies to pursue QS as a therapeutic focus was aptly named Quorum Sciences
(IA, USA). The focus of the company survives
through acquisition by Vertex Pharmaceuticals
(MA, USA) and subsequent research has reported
the discovery of novel specific inhibitors of the
P. aeruginosa QS system. The researchers concluded that the novel QS inhibitors might be useful chemical tools, but not drug leads. However,
the potential for targeted intervention of bacterial
communication channels remains an intriguing
avenue for future drug-development efforts.
Implementation hurdles
These compelling examples also bring to light
hurdles that pharmaceutical companies face as
they develop targeted antimicrobials. A bacteriocin or phage will not be sold as a single molecule; the most promising therapeutic formulations will almost certainly require a cocktail
of bacteriocins or phages. The US regulatory
system is designed to handle one-size-fits-all
drugs, not individual tailored therapeutic combinations. Under existing regulations, the FDA
would require every phage to go through a multiyear testing process – by which time the bug
will almost certainly have evolved again. One
possibility is that the FDA could revise its rules
as it has for the influenza vaccine: although it is
reformulated every year to maintain effectiveness, new versions do not need to repeat the
entire testing process. Our experiences with HIV
drug combinations and influenza vaccines have
proven the power of having a nimble, responsive
regulatory system.
future science group
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A targeted example
To illustrate the potential power of targeted
drugs, we briefly consider the efficacy and utility
of the use of targeted drugs in the treatment of
UTIs and, in particular, catheter-acquired UTIs
(CAUTIs). Most UTIs and CAUTIs are caused
by E. coli, normally a commensal resident of the
large intestine [92,93]. Other Gram-negative bacteria are sometimes involved and include Klebsiella spp., Enterobacter spp., Serratia spp., Proteus
mirabilis and P. aeruginosa [93–95]. These infections are widespread in the human population,
with over 150 million people infected worldwide
each year [96–99]. Women are especially prone to
UTIs: approximately one in five women develops a UTI during her lifetime, with many experiencing life-long recurrences of urinary tract
disease [96,100–102]. In addition, CAUTIs are the
most common form of nosocomial infection
in acute care hospitals and such infections are
almost universally present among patients with
chronic in-dwelling catheters, both in the community and in long-term care facilities [103]. One
study estimated that the cost of UTIs (including
direct costs and indirect losses in productivity
due to illness or hospitalization) reaches $1.6
billion per year in the USA alone, excluding the
costs of catheter-based infections [100].
High levels of antibiotic resistance among the
strains responsible for UTIs are creating a challenge to effective therapy [92,93,98,104–110]. Ampicillin and amoxicillin, formerly the cornerstones
of UTI therapy, are no longer preferred because
future science group

of high levels of resistance. Trimethoprim–
sulfamethoxazole (TMP–SMX) was considered
the drug of choice for uncomplicated UTIs
due to its low cost and well-established efficacy
[111,112]. However, levels of resistance to TMP–
SMX in E. coli now, unfortunately, range from
18 to >30% suggesting that it will soon no longer be effective as a first-line therapeutic option
[107,113,114]. Nitrofurantoin and fluoroquinolones,
such as ciprofloxacin, are also sometimes used as
alternatives to TMP–SMX for treatment of UTIs.
Aminoglycosides, such as gentamicin, are used to
treat severe infections. Their practical use, however, is limited due to high associated toxicity. A
physician treating a UTI or CAUTI now faces a
complex therapeutic landscape. Given that UTIs
are the single most common nosocomial infection, the impact on resistance for this disease
alone is incalculable and, perhaps, avoidable.
The authors and others have initiated investigations to explore the therapeutic potential
of targeted treatments for UTIs [115–121]. One
approach involves the use of bacteriocins. Many
studies attest to the fact that bacteriocins able
to kill or inhibit each of the primary UTI
and CAUTI pathogens already exist [117–121].
Figure 2 represents the activity of a small sample
100
90

Traditional antibiotics
Novel and known bacteriocins

80
Inhibitory percentage (%)

Why have we not already capitalized on the
existing diversity of these potent, targeted antimicrobials? One component of the answer is
straightforward: until recently, physicians relied
on symptom-based diagnosis and, thus, were
often uncertain of the identity of the infecting
agent(s). If the infection was bacterial-based,
use of a broad-spectrum drug was almost always
effective. However, high levels of pathogen resistance now require that prior to prescription we
first identify an effective antibiotic; thus we have
lost one key prior advantage to broad-spectrum
antibiotics – speed and ease of use. Furthermore,
the rapid development of molecular diagnostic
methods now underway ushers in a different
model for the treatment of infections, and frees us
from our reliance on broad-spectrum antibiotics
[91]. We will soon be in a position to rapidly
identify the infecting culprit(s), determine resistance to available drugs and provide a therapeutic
specifically designed for the situation at hand.
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Figure 2. Inhibitory percentages of 96 uropathogenic Escherichia coli
strains for both tradional antibiotics and novel and known bacteriocins.
Novel bacteriocins are labeled with Greek letters.
am: Ampicillin; cip: Ciprofloacin; cz: Cefazolin; fox: Cefoxitin; ft: Nitrofurantoin;
gm: Gentamicin; sam: Ampicillin/sulbactam; sxt: Trimethoprim.
Adapted with permission from [32] .
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of bacteriocins and antibiotics against uropathogenic E. coli [32]. The bacteriocins are just
as likely to inhibit the pathogens as our most
potent antibiotics. Now, consider the fact that
one can easily produce a sample of bacteriocins
active against each uropathogen species, and
the feasibility of designing therapeutics that
specifically target CAUTI and UTI infections
becomes strikingly clear. As anyone recently
harboring a UTI will attest, there is no culturing prior to prescription, nor is the resistance
of the pathogen determined. Those with the
infection are simply given an antibiotic based
upon the physician’s prior treatment success,
and hope for the best. Given that UTIs and
CAUTIs are generally not fatal, are the leading
causes for prescriptions in the USA and that
current protocols do not require, or even permit,
culturing and resistance determination, what
are the arguments against developing a targeted
therapeutic approach for these infections?
One particularly vexing aspect of CAUTI is
that the bacteria form dense biofilms on catheter surfaces, which are virtually impossible
to eliminate with conventional antibiotics.
In contrast, bacteriocins not only inhibit the
growth of biofilms, but some even break down
existing biofilms [122–124]. Furthermore, if a bacteriocin is applied to the catheter and bladder
immediately following catheter insertion, it is
6
24 h pre-treament
36 h post-treatment

Log cell density (cells/ml)

5

4
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1

0

M1

M2

M3

M4

M5
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Figure 3. In vivo effect of a bacteriocin applied to an established mouse
urinary tract infection. Mice were treated with 2 µg of a colicin bladder wash.
Adapted with permission from [32] .
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able to kill infecting cells before they have the
opportunity to grow and attach to the catheter
[124]. In contrast, an antibiotic wash is not only
ineffective in killing the bacteria, it may even
create a worse situation due to its toxicity to the
bladder cells [125,126].
Bacteriocins have been reported to be effective in vivo in numerous experimental systems
[18,51,55,127–134]. F igure 3 represents the in vivo
effect of a bacteriocin applied to an established
mouse UTI. A relatively small dose of bacteriocin (2 µg) used as a bladder wash eliminated a
well established UTI in four of the seven mice
tested, and significantly reduced uropathogen
frequency in two additional mice [32]. A further
study revealed that simply coating a catheter
with a bacteriocin-producing strain of bacteria
prior to insertion eliminated subsequent biofilm
formation [124]. For numerous additional in vivo
examples see the recent review by Cotter et al [18].
Clearly, it will not be business as usual if a
pharmaceutical company pursues such ‘unconventional’ therapeutics, such as bacteriocins or
phages. Existing business models simply will
not apply. However, we are inching closer to the
precipice where bacterial infections will, once
again, become a leading cause of death in the
USA. Perhaps when that critical place is reached,
and we are forced to admit that we have lost the
race against bacterial pathogens, we will finally
turn our existing antibiotic development paradigm on its head and engage in a more refined
approach to targeting bacterial infections.
Future perspective
In this short perspective we can only lightly
touch on the compelling features of targeted
antibacterials that make them such an attractive candidate for therapeutic development. The
features include their targeted specificity, limited
impact on the normal healthy microflora of the
patient, significant reduction in the selective
pressures for resistance emergence, a long history
of use in food preservation, mounting evidence
of their limited toxicity to mammalian cells,
ease of production and their stable nature. Their
potential as therapeutic agents remains largely
untapped. However, all of the early signs suggest
that these potent, naturally occurring families of
toxins provide a compelling, ecologically sound
alternative for the treatment of infectious disease.
This new ecologically based conception of the
importance of the human microbiome in health
may be the single most significant development
in our perception of the microbial world since
future science group
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Pasteur’s germ theory of the 1860s. Its implications for our understanding of health and
pathogenesis are profound. Coupled with the
revolution in diagnostics that we are now witnessing – a revolution that changes medicine
from a science of symptoms to a science of causes
– we cannot continue to develop antibiotics as
we have for the past 80 years. Instead, we need
to usher in a new view of the role of antibiotics
in treatment: away from single molecules that
target broad phylogenetic spectra and towards
targeted molecules that cripple the pathogen
while leaving the rest of the microbiome largely
intact. Similarly, while it is certain that resistance will always evolve in the face of selection,
we can begin to incorporate the lessons learned
in the design and deployment of treatments that
delay the onset of resistance mechanisms. We
cannot, and need not, continue to do the same

| Perspective

thing and expect different outcomes. Instead,
the time has come for a new smarter and more
agile approach to the delicate balance between
pathogens and their hosts.
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Executive summary


For the first time since the discovery of antibiotics, we face the prospect of untreatable infections.



With no magic bullets on the horizon, we have the opportunity to radically rethink how we identify and develop novel antimicrobials.



We contend that resistibility and specificity should become primary design criteria, to both limit the spread of resistance and reduce the
collateral damage on the human microbiome.



Two large families of naturally occurring antimicrobials, the bacteriocins and bacteriophages, offer compelling targeted alternatives to
conventional antibiotics.



Such a dramatic shift in drug-development strategies brings to light numerous challenging regulatory issues and requires companies to
explore new business models.



However, we contend that the time has come for a new smarter and more agile approach to the delicate balance between pathogens
and their hosts.
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